RxDoctor Payments Data

Lawrence Mora, MD

Family Medicine · Los Angeles, CANPI 1205851615

Payments from drug & device makers

$5,809in general payments, 2019–2025

Across 271 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$766
  • Johnson & Johnson$597
  • Novartis$537
  • Amgen$456
  • AbbVie$367
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$344
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,794100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,809 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$84,851
Medicare patients
213
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$494,140
OzempicSemaglutide39$48,208
JardianceEmpagliflozin49$45,665
JanuviaSitagliptin Phosphate60$45,647
EliquisApixaban40$32,402
XareltoRivaroxaban24$26,214
MounjaroTirzepatide18$23,540
FarxigaDapagliflozin Propanediol16$21,098
EntrestoSacubitril/Valsartan17$16,877
LinzessLinaclotide24$15,899
TrulicityDulaglutide13$12,581
Breo ElliptaFluticasone/Vilanterol16$9,425
Albuterol Sulfate HfaAlbuterol Sulfate172$6,754
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$5,592
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen206$5,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$171$48,20839 claims
Boehringer IngelheimJardiance$118$45,66549 claims
MerckJanuvia$22$45,64760 claims
Lilly USA, LLCMounjaro, Trulicity$75$36,12231 claims
PfizerEliquis$108$32,40240 claims
Johnson & JohnsonXarelto$597$26,21424 claims
AstraZenecaFarxiga$766$21,09816 claims
NovartisEntresto$537$16,87717 claims
AbbVieLinzess$367$15,89924 claims
GSKBreo Ellipta, Anoro Ellipta$190$14,55728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →